Vericel Corporation is a commercial-stage biopharmaceutical company that develops and manufactures cellular therapies and specialty biologic products focused on sports medicine and severe burn care. The company operates primarily in North America, with operations centered in Cambridge, Massachusetts.
The company markets three main products across its portfolio. MACI is an autologous cultured chondrocyte therapy delivered on a porcine collagen membrane, indicated for repair of symptomatic cartilage defects of the knee. Epicel is a permanent skin replacement device classified as a humanitarian use device for treatment of deep-dermal or full-thickness burns in adult and pediatric patients. NexoBrid is a biological orphan product used for eschar removal in patients with deep partial-thickness and full-thickness thermal burns. These products target distinct patient populations within the regenerative medicine and trauma care segments.
The company has approximately 357 full-time employees and operates as a Nasdaq-listed entity with a market capitalization of $1.9 billion. Vericel was incorporated in Michigan in 1989 under its former name, Aastrom Biosciences, Inc., before adopting its current name in 2014.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $0.32 | $0.33 | +60.0% | |
| 2024 | $0.20 | $0.21 | +385.7% | |
| 2023 | $-0.07 | $-0.07 | +80.0% | |
| 2022 | $-0.35 | $-0.35 | -118.7% | |
| 2021 | $-0.16 | $-0.16 | -164.0% | |
| 2020 | $0.25 | $0.27 | +25.0% | |
| 2019 | $0.20 | $0.21 | +81.8% | |
| 2018 | $0.11 | $0.12 | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-26 | 0001628280-26-012013 | SEC ↗ |
| 2024-12-31 | 2025-02-27 | 0001628280-25-008447 | SEC ↗ |
| 2023-12-31 | 2024-02-29 | 0001628280-24-007824 | SEC ↗ |
| 2022-12-31 | 2023-02-23 | 0001628280-23-004714 | SEC ↗ |
| 2021-12-31 | 2022-02-24 | 0001628280-22-003661 | SEC ↗ |
| 2020-12-31 | 2021-02-24 | 0001628280-21-003081 | SEC ↗ |
| 2019-12-31 | 2020-02-25 | 0001628280-20-002229 | SEC ↗ |
| 2018-12-31 | 2019-02-26 | 0001628280-19-002007 | SEC ↗ |
| 2017-12-31 | 2018-03-05 | 0001628280-18-002753 | SEC ↗ |
| 2016-12-31 | 2017-03-13 | 0001628280-17-002492 | SEC ↗ |
| 2015-12-31 | 2016-03-14 | 0001628280-16-012668 | SEC ↗ |
| 2014-12-31 | 2015-03-25 | 0001104659-15-022712 | SEC ↗ |
| 2013-12-31 | 2014-03-13 | 0001104659-14-019344 | SEC ↗ |
| 2012-12-31 | 2013-03-18 | 0001104659-13-021790 | SEC ↗ |